US 11857574
Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
granted A61KA61K2239/31A61K2239/38
Quick answer
US patent 11857574 (Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence) held by CRISPR THERAPEUTICS AG expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG
- Grant date
- Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K2239/31, A61K2239/38, A61K2239/48, A61K2239/54